T A G TREATMENT ACTION GROUP INC

Financials

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended December 31, 2024, highest compensation first.

Address and contacts

Address (IRS master file)

90 BROAD ST STE 2503, NEW YORK, NY 10004-2268

Principal officer (990 for 2024)

IVY KWAN ARCE, 90 BROAD STREET 2503, NEW YORK, NY 10004

Signed the 990

IVY KWAN ARCE, PRESIDENT

Phone

(212) 253-7922

Website

WWW.TREATMENTACTIONGROUP.ORG

Return prepared by

LUTZ AND CARR CPAS LLP

Mission

TREATMENT ACTION GROUP (TAG) IS AN INDEPENDENT, ACTIVIST, AND COMMUNITY-BASED RESEARCH AND POLICY THINK TANK COMMITTED TO RACIAL, GENDER, AND LGBTQ+ EQUITY; SOCIAL JUSTICE; AND LIBERATION, FIGHTING TO END HIV, TUBERCULOSIS (TB), AND HEPATITIS C VIRUS (HCV).TAG CATALYZES OPEN COLLECTIVE ACTION BY AFFECTED COMMUNITIES, SCIENTISTS, AND POLICYMAKERS TO ENSURE THAT ALL PEOPLE LIVING WITH OR IMPACTED BY HIV, TB, OR HCV - ESPECIALLY COMMUNITIES OF COLOR AND OTHER MARGINALIZED COMMUNITIES EXPERIENCING INEQUITIES - RECEIVE LIFE-SAVING PREVENTION, DIAGNOSIS, TREATMENT, CARE, AND INFORMATION.WE ARE SCIENCE-BASED ACTIVISTS WORKING TO EXPAND AND ACCELERATE VITAL RESEARCH AND EFFECTIVE COMMUNITY ENGAGEMENT WITH RESEARCH AND POLICY INSTITUTIONS FOR AN END TO THE HIV, TB, AND HCV PANDEMICS.

Program accomplishments

• SEE SCHEDULE OTUBERCULOSIS (TB) PROGRAMACCORDING TO THE LATEST REPORT FROM THE WORLD HEALTH ORGANIZATION (WHO), IN 2023, TB PROBABLY RETURNED TO BEING THE WORLD'S LEADING CAUSE OF DEATH FROM A SINGLE INFECTIOUS AGENT, FOLLOWING 3 YEARS IN WHICH IT WAS REPLACED BY CORONAVIRUS DISEASE (COVID-19), AND CAUSED ALMOST TWICE AS MANY DEATHS AS HIV/AIDS. MORE THAN 10 MILLION PEOPLE CONTINUE TO FALL ILL WITH TB EVERY YEAR AND THE NUMBER HAS BEEN RISING SINCE 2021. URGENT ACTION IS REQUIRED TO END THE GLOBAL TB EPIDEMIC BY 2030, A GOAL THAT HAS BEEN ADOPTED BY ALL MEMBER STATES OF THE UNITED NATIONS (UN) AND THE WORLD HEALTH ORGANIZATION (WHO)." RECOGNIZING THAT MUCH MORE PROGRESS COULD BE MADE IF EXISTING TOOLS WERE FULLY IMPLEMENTED, AND THAT MORE RESEARCH IS NEEDED TO END TB, TAG'S TB PROGRAM STRENGTHENS EVIDENCE-DRIVEN AND HUMAN RIGHTS-BASED ADVOCACY BOTH FOR BETTER TB RESEARCH, AND FOR HIGH-QUALITY PROGRAMS AND POLICIES WORLDWIDE, THAT MEET THE NEEDS OF AFFECTED COMMUNITIES.TAG'S TB PROGRAM EDUCATES, MOBILIZES, AND EMPOWERS COMMUNITIES TO INCREASE UNDERSTANDING OF TB AND TO CATALYZE ACTION TO REDUCE NEW INFECTIONS, DEATHS, AND SUFFERING FROM TB AND TB/HIV. THE PROGRAM WORKS WITH COMMUNITY ADVOCATES, COMMUNITY ADVISORY BOARDS, RESEARCHERS, POLICY MAKERS, DEVELOPERS, AND DONORS TO ENSURE NEEDS-DRIVEN RESEARCH TO IMPROVE OPTIONS FOR TB PREVENTION, DIAGNOSIS, AND TREATMENT. THE TB PROGRAM PUBLISHES AN ANNUAL REPORT ON TB RESEARCH FUNDING TRENDS, AND ADVOCATES FOR ALL GOVERNMENTS OF THE WORLD TO STEP UP AND CONTRIBUTE THEIR "FAIR SHARE" INVESTMENTS IN TB R&D.THE TB PROGRAM WORKS WITH RESEARCHERS, ACTIVISTS, AND POLICYMAKERS AROUND THE WORLD TO ENSURE TRANSPARENCY AND UNIVERSAL, EQUITABLE, AFFORDABLE ACCESS TO PROVEN INTERVENTIONS, FROM EARLY IN THE RESEARCH PROCESS THROUGH REGULATORY APPROVAL TO GLOBAL AND NATIONAL GUIDELINES DEVELOPMENT AND PRODUCT PRICING. TAG'S POLICY TEAM SUPPORTS THE TB PROGRAM IN EDUCATING U.S. LEGISLATORS AND OFFICIALS ON TB PRIORITIES, AND LEADS DOMESTIC WORK AT THE LOCAL, STATE, AND NATIONAL LEVEL TO SUPPORT AMBITIOUS AND EVIDENCE-BASED PROGRAMMING TO END.
  Expenses $2,150,585 · grants $654,930 · revenue $29,185
• SEE SCHEDULE OHIV PROGRAMACCORDING TO THE JULY 2025 UNAIDS GLOBAL AIDS REPORT, "40.8 MILLION [37.0 MILLION-45.6 MILLION] PEOPLE GLOBALLY WERE LIVING WITH HIV IN 2024. 1.3 MILLION [1 MILLION-1.7 MILLION] PEOPLE BECAME NEWLY INFECTED WITH HIV IN 2024. 630 000 [490 000-820 000] PEOPLE DIED FROM AIDS-RELATED ILLNESSES IN 2024. 31.6 MILLION PEOPLE [27.8-32.9 MILLION] WERE ACCESSING ANTIRETROVIRAL THERAPY IN 2024. 91.4 MILLION [73.4 MILLION-116.4 MILLION] PEOPLE HAVE BECOME INFECTED WITH HIV SINCE THE START OF THE EPIDEMIC. 44.1 MILLION [37.6 MILLION-53.4 MILLION] PEOPLE HAVE DIED FROM AIDS-RELATED ILLNESSES SINCE THE START OF THE EPIDEMIC." ACCORDING TO THE U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) 2025 UPDATE, THERE WERE OVER 39,000 PEOPLE NEWLY DIAGNOSED WITH HIV, ALMOST 4,500 HIV-RELATED DEATHS, AND OVER 1,132,000 AMERICANS LIVING WITH HIV BY THE END OF 2023.TAG'S HIV PROGRAM WORKS TO MAXIMIZE EQUITABLE, AFFORDABLE ACCESS TO THE TOOLS, SERVICES, POLICIES, AND APPROACHES TO PREVENTION AND CARE THAT ARE ESSENTIAL FOR THE GOAL OF ENDING THE HIV EPIDEMIC DOMESTICALLY AND GLOBALLY. ADVOCACY FOCUSED ON ENDING THE EPIDEMIC (ETE, OR EHE) IS AT THE CORE OF THE HIV PROGRAM'S WORK, FROM DRIVING THE NATION'S FIRST ETE INITIATIVE IN NEW YORK TO LEADING THE ACT NOW: END AIDS (ANEA) COALITION'S SUPPORT FOR PARTNERS IN HEAVILY BURDENED JURISDICTIONS IN THE SOUTHERN U.S. TAG'S HIV AND POLICY TEAMS TACKLE ISSUES AROUND DRUG PRICING AND EQUITABLE ACCESS TO EMERGING BIOMEDICAL INTERVENTIONS; FUNDING FOR EVIDENCE-BASED HIV PROGRAMMING; ACCESS TO HEALTHCARE; AND POLICIES THAT PROMOTE SAFE, INCLUSIVE ENVIRONMENTS THAT ARE FREE OF STIGMA AND DISCRIMINATION FOR PEOPLE TO SEEK PREVENTION AND CARE FOR HIV AND RELATED INFECTIONS, INCLUDING SEXUALLY TRANSMITTED INFECTIONS.TAG'S HIV PROGRAM LEADS RESEARCH ACTIVISM AND PROMOTES COMMUNITY ENGAGEMENT TO ENSURE THAT PEOPLE LIVING WITH HIV EVERYWHERE HAVE MORE OPTIONS INCLUDING, ULTIMATELY, A SAFE AND EFFECTIVE HIV VACCINE AND A CURE THAT ARE SCALABLE, AFFORDABLE, AND CAN BE USED WORLDWIDE. TAG'S HIV PROGRAM RECOGNIZES THAT EVEN THE MOST EFFECTIVE EXISTING PREVENTION AND TREATMENT INTERVENTIONS HAVE SHORTCOMINGS. TO THIS END, TAG'S BASIC SCIENCE, VACCINE AND CURE PROJECT TRACKS THE ANTIRETROVIRAL, CURE, IMMUNE-BASED THERAPY, AND BIOMEDICAL PREVENTION PIPELINES AND PUBLISHES ANNUAL REPORTS SUMMARIZING THEIR CURRENT STATUS. TAG ALSO PLAYS A VITAL LEADERSHIP ROLE IN BASIC SCIENCE, VACCINES, AND CURE ADVOCACY, PARTICIPATING IN COMMUNITY ADVISORY BOARDS AND ADMINISTERING AN EMAIL DISCUSSION LISTSERV FOR STAKEHOLDERS IN HIV CURE AND IMMUNE-BASED THERAPY RESEARCH. IN 2024, TAG CONTRIBUTED TO THE NEW U.S. NATIONAL INSTITUTES OF HEALTH (NIH) STRATEGIC PLAN FOR HIV AND HIV-RELATED RESEARCH, COVERING 2026-2030. DURING THE PLANNING PROCESS, TAG'S HIV PROJECT STAFF SERVED ON THE NIH OFFICE OF AIDS RESEARCH BASIC BIOMEDICAL AND PRECLINICAL RESEARCH TASKFORCE. TAG'S HIV CURE-RELATED CLINICAL TRIALS WEBSITE LISTING, UPDATED MONTHLY TO PROVIDE INFORMATION ON STUDIES AND THEIR RESULTS, IS WIDELY CITED IN SCIENTIFIC PAPERS AND IN CONFERENCE PRESENTATIONS. THE HIV PROGRAM ALSO ADVOCATES FOR APPROPRIATE INTERVENTIONS FOR PEOPLE WHO, DESPITE HIV TREATMENT, STILL HAVE POOR IMMUNE SYSTEM RECOVERY. CENTRAL TO THIS WORK IS ENSURING LEGISLATORS AND POLICY MAKERS UNDERSTAND THE ONGOING NEEDS FOR RESEARCH AND HIV-RELATED FUNDING, AND HOW IMPORTANT IT IS TO MAKE DECISIONS BASED ON SCIENTIFIC EVIDENCE.TAG STAFF CONTINUE TO PARTICIPATE AS MEMBERS OF THE PREP IN BLACK AMERICA COALITION, A NETWORK OF ADVOCATES WORKING TO INCREASE EQUITABLE ACCESS AND UPTAKE OF PRE-EXPOSURE PROPHYLAXIS FOR HIV PREVENTION, WHICH IN APRIL 2024 HOSTED A RESEARCH-FOCUSED PRE-CONFERENCE AHEAD OF THE NMAC BIOMEDICAL HIV PREVENTION SUMMIT. TAG ALSO CONTINUES TO LEAD AND CO-ORGANIZE COMMUNITY ENGAGEMENT ACTIVITIES ON HIV CURE RESEARCH, INCLUDING THE ANNUAL PRE-CROI COMMUNITY HIV CURE RESEARCH WORKSHOP, AND CONTINUES TO MAINTAIN THE ONLY KNOWN DATABASE MONITORING THE DEMOGRAPHICS OF PARTICIPANTS IN HIV CURE-FOCUSED CLINICAL TRIALS. ALL WEBINARS AND MATERIALS PRODUCED BY THE HIV PROGRAM ARE AVAILABLE ON TAG'S WEBSITE.IN 2024, TAG'S HIV PROGRAM CONDUCTED COMMUNITY ENGAGEMENT ACTIVITIES ON THE TOPICS OF BIOMEDICAL HIV PREVENTION, ENHANCING PRIOR AND CURRENT PROGRAMMING THROUGH SEVERAL WEBINARS FOCUSED ON TOPICS SUCH IMPLEMENTATION OF LONG-ACTING INJECTABLE HIV TREATMENT AND PREVENTION, AS WELL AS COVERING HIV AWARENESS, SEXUAL AND REPRODUCTIVE HEALTH AMONG YOUNG PEOPLE. EDUCATION AND HEALTH PROMOTION WAS ALSO ENHANCED BY TAG'S SOCIAL MEDIA AMBASSADORSHIP PROGRAM IN COLLABORATION WITH THE HIV VACCINE TRIALS NETWORK, AND SOUTHERN AIDS COALITION, COLLABORATION WITH THE PREP IN BLACK AMERICA COALITION; AND INCLUDING REAL-TIME COVERAGE OF SEVERAL IMPORTANT CONFERENCES, MEETINGS AND EVENTS ATTENDED BY HEAVILY AFFECTED COMMUNITIES, SUCH AS THE HIV VACCINE TRIALS NETWORK (HVTN) FULL GROUP MEETING, THE AIDS WALK NY, THE NATIVE SON AWARDS, THE SAVING OURSELVES SYMPOSIUM HOSTED BY SOUTHERN AIDS COALITION, AND THE U.S. CONFERENCE ON HIV AND AIDS, AMONG OTHERS. THE TAG HIV PROGRAM CULMINATED WITH A WORLD AIDS DAY TOWN HALL FORUM CO-HOSTED BY TAG IN COLLABORATION WITH SIRIUSXM. SINCE 2024, THE ACT NOW: END AIDS (ANEA) COALITION HAS CONTINUED TO ACHIEVE SIGNIFICANT MILESTONES IN ITS MISSION TO COMBAT HIV/AIDS AND PROMOTE EQUITABLE ACCESS TO CARE, THROUGH STRATEGIC CONVENINGS, POLICY ENGAGEMENT, AND KNOWLEDGE-BUILDING INITIATIVES. IN 2024, ANEA HOSTED REGULAR COALITION MEETINGS TO ALIGN EFFORTS ACROSS THE SOUTH AND NATIONALLY, AND HELD A CONGRESSIONAL BRIEFING ON THE ENDING THE HIV EPIDEMIC (EHE) INITIATIVE TO UPLIFT THE VOICES AND PRIORITIES OF PEOPLE LIVING WITH HIV. WE PARTNERED WITH THE TEXAS STRIKE FORCE TO DELIVER A WEBINAR HIGHLIGHTING GRASSROOTS STRATEGIES FOR STATE-LEVEL ADVOCACY, AND DESIGNED MULTIPLE WORKSHOPS AT USCHA 2024, WHICH CULMINATED IN A PUBLISHED PAPER CENTERING BLACK WOMEN'S BODILY AUTONOMY IN THE CONTEXT OF HIV ADVOCACY. ADDITIONALLY, ANEA BEGAN WORKING WITH A PUBLICATION DESIGN CONSULTANT TO ADVANCE THE PRODUCTION OF A COMPREHENSIVE EHE READINESS ASSESSMENT IN COLLABORATION WITH PARTNER JURISDICTIONS, CONSISTING OF A DETAILED SURVEY AND KEY INFORMANT INTERVIEWS. THIS ASSESSMENT WILL PROVIDE KEY UNDERSTANDING OF THE SUCCESSES AND CHALLENGES ENCOUNTERED IN UTILIZING EHE FUNDS TO REACH HIGHLY-IMPACTED COMMUNITIES. THROUGH THESE EFFORTS, ANEA CONTINUES TO FOSTER LEADERSHIP, STRENGTHEN PARTNERSHIPS, AND ADVANCE POLICY ROOTED IN LIVED EXPERIENCE.
  Expenses $906,992 · grants $8,308
• SEE SCHEDULE OHEPATITIS C VIRUS (HCV) PROGRAMACCORDING TO THE WORLD HEALTH ORGANIZATION'S GLOBAL HEPATITIS REPORT 2024, OF THE 50 MILLION PEOPLE ESTIMATED TO BE LIVING WITH CHRONIC HEPATITIS C VIRUS INFECTION, ONLY 36% WERE DIAGNOSED BETWEEN 2015 AND 2022, AND 20% RECEIVED TREATMENT. IN 2022 ALONE, ABOUT 1 MILLION NEW HCV INFECTIONS AND APPROXIMATELY 221 000 HCV-RELATED DEATHS WERE REGISTERED, MOSTLY FROM CIRRHOSIS AND HEPATOCELLULAR CARCINOMA.[1] ABOUT 2.3 MILLION PEOPLE (6.2%) OF THE ESTIMATED 37.7 MILLION LIVING WITH HIV GLOBALLY IN 2020 HAD SEROLOGICAL EVIDENCE OF PAST OR PRESENT HCV INFECTION.TAG'S HCV PROGRAM HAS BEEN AT THE FOREFRONT OF A GLOBAL HCV EDUCATION AND ADVOCACY MOVEMENT, WORKING IN COLLABORATION WITH AFFECTED COMMUNITIES, SCIENTISTS, GOVERNMENTS, AND DRUG COMPANIES TO MAKE LIFE-SAVING INFORMATION, HIGH QUALITY AND AFFORDABLE TESTING AND CURES, AND ENSURING A SUPPORTIVE ENVIRONMENT FOR UNDERSERVED POPULATIONS UNIVERSALLY. THIS INCLUDES TRACKING THE PIPELINE FOR HCV INNOVATIONS, INCLUDING THE LATEST PANGENOTYPIC TREATMENTS, DIAGNOSTICS, AND LONG-ACTING INJECTABLES, AND INCREASING COMMUNITIES' DIAGNOSTICS AND TREATMENT LITERACY. GLOBALLY, TAG PROVIDES TECHNICAL ASSISTANCE TO BUILD LEADERSHIP CAPACITY FOR ADVANCING NATIONAL ELIMINATION CAMPAIGNS AND AMPLIFYING COMMUNITY VOICES-ESPECIALLY THOSE OF KEY POPULATIONS SUCH AS PEOPLE WHO USE DRUGS, SEX WORKERS, PEOPLE IN INCARCERATION, MIGRANTS, AND MEN WHO HAVE SEX WITH MEN IN PLANNING AND POLICY DEVELOPMENT. TAG'S HCV PROGRAM WORKS TO OVERCOME BARRIERS TO HCV PREVENTION AND CARE, INCLUDING LIMITED DONOR FUNDING FOR HCV, RESTRICTIONS IMPOSED BY GOVERNMENTS AND PAYERS, PATENTS, PRICING BARRIERS, INEFFECTIVE VOLUNTARY LICENSING AND DELAYS IN DRUG REGISTRATION BY ORIGINATOR COMPANIES. THE HCV PROGRAM ADVOCATES FOR HARM REDUCTION AND DRUG DECRIMINALIZATION EFFORTS, INCLUDING SUPPORT FOR OVERDOSE PREVENTION AND SAFE CONSUMPTION SITES AS UNSAFE INJECTION DRUG USE IS A MAJOR ROUTE OF HCV TRANSMISSION.IN THE U.S., TAG'S POLICY TEAM WORKS AT THE LOCAL, STATE, AND NATIONAL LEVELS: ADVOCATING FOR VIRAL HEPATITIS FUNDING, CHAMPIONING TREATMENT COVERAGE FOR PEOPLE WHO USE DRUGS, PEOPLE WHO ARE UNSTABLY HOUSED AND INCARCERATED OR OTHERWISE MARGINALIZED PEOPLE, ENCOURAGING VOLUME-BASED PRICING DEALS FOR DAAS, STRENGTHENING NATIONAL SURVEILLANCE, AND SUPPORTING COMMUNITY ENGAGEMENT. TAG'S ADVOCACY HELPED ADVANCE COVERAGE FOR UNIVERSAL ADULT HCV SCREENING AND DRIVE NEW YORK STATE'S COMMITMENT TO ELIMINATE HCV -- THE FIRST IN THE NATION! -- WITH TAG PARTICIPATING IN THE RESULTANT STATEWIDE HCV ELIMINATION TASK FORCE.
  Expenses $297,189 · grants $23,179
• Expenses $22,387

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

IRS record

EIN

13-3624785

Tax-exempt status

501(c)(3): Charitable, religious, educational or scientific organization

Foundation status

Publicly supported organization (170(b)(1)(A)(vi))

Donations deductible (Pub 78)

Public charity, 50% deduction limit

Exempt since

1993

Accounting year ends

December

Files

Form 990 or 990-EZ

Category (NTEE)

Unknown (Z99Z)

Assets (IRS master file)

$3,839,139

Income (IRS master file)

$3,619,941

Filing history

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 13-3624785).

Questions about T A G TREATMENT ACTION GROUP INC

What is the EIN of T A G TREATMENT ACTION GROUP INC?

The employer identification number (EIN) of T A G TREATMENT ACTION GROUP INC is 13-3624785.

Is T A G TREATMENT ACTION GROUP INC tax-exempt?

Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 1993.

Are donations to T A G TREATMENT ACTION GROUP INC tax-deductible?

Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).

Which annual return does T A G TREATMENT ACTION GROUP INC file?

Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.

When is the next return of T A G TREATMENT ACTION GROUP INC due?

The return for tax year 2025 (the year ending December 31, 2025) is due May 15, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.

When did T A G TREATMENT ACTION GROUP INC last file with the IRS?

The latest return in the IRS public files is the 990 for the year ended December 2024.

Who is the principal officer of T A G TREATMENT ACTION GROUP INC?

The 990 for the year ended December 31, 2024 names IVY KWAN ARCE.

Who are the officers and directors of T A G TREATMENT ACTION GROUP INC?

The 990 for the year ended December 31, 2024 lists 23 people; 6 received compensation from the organization, the highest $193,628 (MARK HARRINGTON, EXECUTIVE DIRECTOR).

How much revenue does T A G TREATMENT ACTION GROUP INC have?

On its 990 for the year ended December 31, 2024 it reported revenue of $3,574,921, expenses of $4,092,642 and total assets of $3,839,139 at year end.

Other nonprofits in NEW YORK

• COMUNILIFE INC
  EIN 13-3530299 · last filed 990 for 2025
• TIMES SQUARE DISTRICT MANAGEMENT ASSOCIATION
  EIN 13-3627527 · last filed 990 for 2025
• OUTRIGHT ACTION INTERNATIONAL
  EIN 94-3139952 · last filed 990 for 2025
• AVI CHAI FOUNDATION
  EIN 13-3252800 · last filed 990-PF for 2024
• CATALYST INC
  EIN 13-1992402 · last filed 990 for 2025
• 50 BROADWAY REALTY CORP
  EIN 02-0555262 · last filed 990 for 2025
• 52 BROADWAY REALTY CORP
  EIN 02-0555237 · last filed 990 for 2025
• THE PIERRE AND TANA MATISSE FOUNDATION
  EIN 13-3838457 · last filed 990-PF for 2024

All nonprofits in NEW YORK · New York · Unknown